{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:01:30Z","timestamp":1788620490977,"version":"build-2803163510"},"reference-count":40,"publisher":"Informa UK Limited","issue":"5","funder":[{"DOI":"10.13039\/100019832","name":"Galapagos","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AbbVie"},{"name":"Janssen"},{"name":"Genentech"},{"name":"Alimentiv"},{"name":"Ferring Pharmaceuticals"},{"DOI":"10.13039\/501100012276","name":"Tillotts Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012276","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018592","name":"Celltrion","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Takeda"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"InDex Pharmaceuticals"},{"name":"Sandoz"},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Samsung Bioepis"},{"name":"Inotrem"},{"name":"Allergan"},{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Roche"},{"DOI":"10.13039\/100022789","name":"Arena Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100022789","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Gilead"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol Myers Squibb"},{"name":"CSL Vifor"},{"DOI":"10.13039\/501100023453","name":"Norgine","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023453","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016259","name":"Mylan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016259","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Lilly"},{"DOI":"10.13039\/100017530","name":"Fresenius Kabi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"OSE Immunotherapeutics"},{"name":"Enthera"},{"name":"Theravance Biopharma"},{"name":"Pandion Therapeutics"},{"name":"Gossamer Bio"},{"name":"Viatris"},{"DOI":"10.13039\/100011033","name":"Thermo Fisher Scientific","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011033","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Mopac"},{"name":"Cytoki Pharma"},{"name":"Morphic Therapeutic"},{"name":"Prometheus Biosciences and Applied Molecular Transport"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.2217\/imt-2022-0255","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T08:24:25Z","timestamp":1676449465000},"page":"311-321","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":24,"title":["Etrasimod for the Treatment of Ulcerative Colitis"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7684-6067","authenticated-orcid":false,"given":"Pauline","family":"Wils","sequence":"first","affiliation":[{"name":"Inserm, CHU Lille, U1286\u00a0- INFINITE - Institute for Translational Research in Inflammation, University of Lille, F-59000Lille, France"},{"name":"Department of Gastroenterology, Centre Hospitalier R\u00e9gional Universitaire de Lille, University of Lille, 59000, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"University of Lorraine, CHRU-Nancy, Department of Gastroenterology, F-54000Nancy, France"},{"name":"University of Lorraine, Inserm, NGERE, F-54000Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21863"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2002697"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X14558193"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000496739"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32448-0"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.06.016"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520802600961"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy004"},{"key":"e_1_3_4_11_1","first-page":"izac119","article-title":"Comparative acceptability of therapeutic maintenance regimens in patients with inflammatory bowel disease: results from the nationwide ACCEPT2 study","author":"Buisson A","year":"2022","unstructured":"Buisson A , SerreroM , OrsatLet al. Comparative acceptability of therapeutic maintenance regimens in patients with inflammatory bowel disease: results from the nationwide ACCEPT2 study. Inflamm. Bowel Dis.izac119 (2022).","journal-title":"Inflamm. Bowel Dis."},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.01.010"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15297"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22030344"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00244-0"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033617"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml500389m"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.254268"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1732919"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.06.028"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1113640"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12272"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature02284"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00574-7"},{"key":"e_1_3_4_26_1","volume-title":"Advances in Inflammatory Bowel Diseases","author":"Schreiber S","year":"2016","unstructured":"Schreiber S , MorganM , ChristopherRet al. Etrasimod (APD334), a potent, selective, oral S1P receptor modulator with preclinical autoimmune disease-modifying activity exhibits favorable PK\/PD properties in healthy volunteers. Presented at: Advances in Inflammatory Bowel Diseases. Orlando, FL, USA, 8\u201310 December 2016."},{"key":"e_1_3_4_27_1","volume-title":"13th Congress of the European Crohn\u2019s and Colitis Organisation","author":"Peyrin-Biroulet L","year":"2018","unstructured":"Peyrin-Biroulet L , AdamsJ , TurnerSet al. Safety and immune modulatory properties of etrasimod (APD334), a next-generation oral, selective sphingosine 1-phosphate receptor (S1PR) modulator, in healthy volunteers. Presented at: 13th Congress of the European Crohn\u2019s and Colitis Organisation. Vienna, Austria, 14\u201317 February 2018."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.10.035"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab016"},{"key":"e_1_3_4_30_1","unstructured":"Oh DA LeeCA TangYet al. Steady-state trough concentrations and their relationship to selected demographic and clinical response measures in etrasimod-treated patients with moderately-to-severely active ulcerative colitis. World Congress of Gastroenterology Istanbul Turkey (2019)."},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2020.1785868"},{"key":"e_1_3_4_32_1","unstructured":"Bristol Myers Squibb Pharma EEIG\n. Zeposia (ozanimod hydrochloride) capsules for oral use: US prescribing information (2021). (Accessed 3August2022). https:\/\/daily med.nlm.nih.gov"},{"key":"e_1_3_4_33_1","unstructured":"Lee CA et al. Mass balance metabolic disposition and pharmacokinetics of [ 14 C] etrasimod following oral administration to healthy male volunteers. American Association of Pharmaceutical Scientists (2019)."},{"issue":"1","key":"e_1_3_4_34_1","first-page":"S36","article-title":"P396 pharmacokinetics and circulating total lymphocyte count pharmacodynamic response from single and multiple oral doses of etrasimod in Japanese and Caucasian healthy male subjects","volume":"14","author":"Lee CA","year":"2020","unstructured":"Lee CA , AcevedoL , OhDAet al. P396 pharmacokinetics and circulating total lymphocyte count pharmacodynamic response from single and multiple oral doses of etrasimod in Japanese and Caucasian healthy male subjects. J. Crohns Colitis14(Suppl. 1), S368 (2020).","journal-title":"J. Crohns Colitis"},{"issue":"1","key":"e_1_3_4_35_1","doi-asserted-by":"crossref","first-page":"i029","DOI":"10.1093\/ecco-jcc\/jjab232.026","article-title":"OP27 a phase 1 study evaluating the bioequivalence of the proposed commercial and clinical formulations of etrasimod 2mg and the effect of food on the pharmacokinetics of the proposed commercial formulation in healthy volunteers","volume":"16","author":"Lee C","year":"2022","unstructured":"Lee C , RamaiyaA , TangYet al. OP27 a phase 1 study evaluating the bioequivalence of the proposed commercial and clinical formulations of etrasimod 2mg and the effect of food on the pharmacokinetics of the proposed commercial formulation in healthy volunteers. J. Crohns Colitis16(Suppl. 1), i029 (2022).","journal-title":"J. Crohns Colitis"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab076.415"},{"issue":"1","key":"e_1_3_4_37_1","first-page":"A142","article-title":"P208 effect of coadministration of etrasimod on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive","volume":"71","author":"Taylor C","year":"2022","unstructured":"Taylor C , TangY , Villa-CaballeroL , LiuK , RandleA , GrundyJS. P208 effect of coadministration of etrasimod on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive. Gut71(Suppl. 1), A142 (2022).","journal-title":"Gut"},{"issue":"1","key":"e_1_3_4_38_1","first-page":"A143","article-title":"P209 etrasimod improves quality of life in adults with moderate-to-severe ulcerative colitis","volume":"71","author":"Taylor C","year":"2022","unstructured":"Taylor C , ChioreanM , VermeireSet al. P209 etrasimod improves quality of life in adults with moderate-to-severe ulcerative colitis. Gut71(Suppl. 1), A143 (2022).","journal-title":"Gut"},{"key":"e_1_3_4_39_1","unstructured":"Pfizer\n. Pfizer presents ELEVATE pivotal findings demonstrating etrasimod\u2019s potentially best-in-class profile in ulcerative colitis. www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-presents-elevate-pivotal-findings-demonstrating"},{"key":"e_1_3_4_40_1","unstructured":"US National Library of Medicine\n. Etrasimod versus placebo as induction therapy in moderately to severely active ulcerative colitis (ELEVATE UC 12). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03996369"},{"key":"e_1_3_4_41_1","unstructured":"US National Library of Medicine\n. Etrasimod versus placebo for the treatment of moderately to severely active ulcerative colitis (ELEVATE UC 52). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03945188"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(22)64063-0"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2022-0255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:04:22Z","timestamp":1715940262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2022-0255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.2217\/imt-2022-0255"],"URL":"https:\/\/doi.org\/10.2217\/imt-2022-0255","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}